Table 4. Baseline clinical characteristics of LBCL patients by SCT status.
| Variable | SCT (n=9) | Non-SCT (n=36) | P value |
|---|---|---|---|
| Age, years (range) | 60(49-69) | 69.5(24-85) | 0.055 |
| Sex | 1.000 | ||
| Male | 6 (67%) | 22 (61%) | |
| Female | 3 (33%) | 14 (39%) | |
| Pathologic type | 0.075 | ||
| DLBCL | 4 (44%) | 28(78%) | |
| FLG3 | 1 (11%) | 3 (8%) | |
| TL | 4 (44%) | 5 (14%) | |
| Stage 4 at diagnosis, number | 3 (33%) | 18(50%) | 0.469 |
| Time from diagnosis, months (range) | 29.6(4-99) | 21.5(4-98) | 0.580 |
| Prior lines of therapy, median (range) | 3 (2-4) | 3 (1-4) | 0.315 |
| International prognostic index score, median (range) | 1 (1-4) | 3 (1-5) | 0.008 |
Abbreviations: LBCL, large B-cell lymphoma; SCT, stem cell transplantation; DLBCL, diffuse large B-cell lymphoma; FLG3,grade 3 follicular lymphoma; TL,transformedlymphoma.